Pralsetinib Patent Expiration
Pralsetinib is used for advanced or metastatic RET fusion-positive thyroid cancer and non-small cell lung cancer in certain patients. It was first introduced by Rigel Pharmaceuticals Inc
Pralsetinib Patents
Given below is the list of patents protecting Pralsetinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Gavreto | US11273160 | RET inhibitor for use in treating cancer having a RET alteration | Apr 03, 2039 | Rigel Pharms |
| Gavreto | US11872192 | RET inhibitor for use in treating cancer having a RET alteration | Apr 03, 2039 | Rigel Pharms |
| Gavreto | US11963958 | RET inhibitor for use in treating cancer having a RET alteration | Apr 03, 2039 | Rigel Pharms |
| Gavreto | US10030005 | Inhibitors of RET | Nov 01, 2036 | Rigel Pharms |
Pralsetinib's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List